Sansure Biotech Inc(688289) announced that the company’s product human papillomavirus nucleic acid detection kit (PCR fluorescent probe method) recently received the medical device registration certificate issued by the State Drug Administration. The product can meet the needs of one tube test and provide three results at the same time – type 16 and 18 typing and 13 other high-risk types. The application scenarios cover outpatient and physical examination. The launch of the product will provide a more comprehensive and accessible integrated service solution for HPV infection.
The New Coronavirus (SARS-CoV-2) L452R/E484K/K417N mutant nucleic acid detection kit (fluorescence PCR method) was recently approved by the Ministry of health of France. The kit can be used for preliminary judgement of the variant of the PCR in the guidelines of the Ministry of health of France. The results can be used to determine whether there are mutations in L452R, E484K and K417N genes in the infected patients. Better assist in rapid epidemic detection and prevention and control.
(Shanghai Securities News · China Securities Network)
